PCSS/AAPM Free CME Webinar:

Demystifying Drug Interactions with Combined Analgesics Across Various Therapeutic Classes

Access a free video recording of this CME-eligible webinar

Requires log-in and the completion of pre-test.

Original Presentation Date: September 19, 2017


Considering drug-drug interactions is key to selecting the safest and most efficacious combinations of analgesic drug classes and adjuvants (e.g., antidepressants, anticonvulsants). In order to appropriately identify drug-drug interactions, it is essential that clinicians understand the relevant common mechanisms for these, in particular those mediated by the cytochrome P450 (CYP450) system and P-glycoprotein. Pharmacogenetic differences among patients can also impact efficacy, drug interactions, and ability to tolerate medications. This webinar will describe opioid and non-opioid pharmacokinetics and drug-drug interactions and their impact on patient analgesia. Adverse effects when combining analgesics will be further explored through cases studies.

Learning Objectives:

After participating in this activity, participants will be better able to:

  1. Classify cytochrome P450 (CYP450) system nomenclature and describe role of CYP450 and p-glycoprotein in pharmacokinetics
  2. Recognize key CYP450 mediated drug-drug interactions
  3. Identify potential drug-drug interactions and important considerations when prescribing various analgesic classes and adjuvants


Larry C. Driver, MD Larry C. Driver, MD
University of Texas Distinguished Teaching Professor,
Department of Pain Medicine,
Section of Integrated Ethics,
The University of Texas M.D. Anderson Cancer Center,
Houston, Texas
Larry C. Driver, MD, is a University of Texas Distinguished Teaching Professor. He is a professor in both the Department of Pain Medicine and in the Section of Integrated Ethics at the University of Texas M.D. Anderson Cancer Center, in Houston, Texas. He is Board Certified in Anesthesiology, Palliative Medicine, and Pain Medicine. Dr. Driver is also currently Chair of the American Academy of Pain Medicine Professional Education and CME Oversight Committee; he is a Mayday Pain & Society Fellow, and has been recognized in several Best Doctors and Top Doctors listings, and has received numerous state and national awards for his advocacy efforts.
Jeffrey Fudin, PharmD, DAAPM, FCCP, FASHP Jeffrey Fudin, PharmD, DAAPM, FCCP, FASHP
Adjunct Associate Professor,
Western New England College of Pharmacy,
Western New England University,
Springfield, Massachussets
PGY2 Pharmacy Pain Residency,
Samuel Stratton VA Medical Center Pharmacy,
Albany, New York
Jeffrey Fudin, PharmD, DAAPM, FCCP, FASHP, graduated from Albany College of Pharmacy & Health Sciences with his Bachelors Degree and PharmD. He completed an Oncology/Hematology fellowship at SUNY/Upstate Medical Center. He is a Diplomate to the American Academy of Pain Management and a Fellow of both the American College of Clinical Pharmacy and the American Society of Health-System Pharmacists. Dr Fudin is a Section Editor for Pain Medicine, Founder/Chairman of Professionals for Rational Opioid Monitoring & Pharmacotherapy, and peer reviewer for several professional journals. He has participated in developing practice guidelines for use of opioids in chronic noncancer pain (an American Pain Society/American Academy of Pain Medicine (AAPM) collaborative) and participated in national and international guideline development for arthritis, fibromyalgia, and palliative Care. He is consultant to a national panel to develop consensus guidelines for the proper use of urine testing in addiction medicine, a collaborative effort with the National Association of Addiction Treatment Providers, Center for Lawful Access and Abuse Deterrence, and the American Society of Addiction Medicine. Dr Fudin practices as a Clinical Pharmacy Specialist and Director, PGY-2 Pharmacy Pain Residency Programs at the Stratton Veterans Administration Medical Center in Albany, New York. He holds adjunct faculty positions at University of Connecticut School of Pharmacy, Western New England University College of Pharmacy in Springfield, Massachusetts, and Albany College of Pharmacy & Health Sciences. Dr Fudin has been an invited speaker on pain management nationally and internationally. Dr Fudin is founder and Chair of Professionals for Rational Opioid Monitoring and Pharmacotherapy (PROMPT), owner and managing editor for, and CEO/founder of Remitigate LLC, a software development company which has launched an application to help clinicians interpret urine drugs screens with several pipeline products, including a pharmacogenetic app. He is a prolific lecturer, writer, and researcher on pain management topics and he served as a Task Force member for the Board of Pharmacy Specialties for role delineation study/practice analysis of pain and palliative care pharmacy. He was awarded the AAPM’s Presidential Commendation in 2014, in recognition as “a voice for scientific integrity and an advocate for people in pain.”

Continuing Education: The American Academy of Pain Medicine (AAPM) provides a live webinar titled “A Shifting Paradigm: From Biomedical to Biopsychosocial Interactions” and offers continuing medical education (CME) for physicians. Successful completion requires that participants register for the webinar and complete a pre-test, attend and participate, and complete an online post-test and evaluation. Participants receive their CME certificates after they submit their evaluations online.

Accreditation: The American Academy of Pain Medicine is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Credit Designation: The American Academy of Pain Medicine designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Learn more about the 2017 PCSS/AAPM webinar series.

Facebook Twitter Linkedin